🔥 The Mega deal: Electra
What: A Paris-based manufacturer of fast-charging EV stations.
Why: To remove all barriers to the adoption of electric cars by deploying the most efficient network of fast-charging stations in Europe and making charging EVs as easy as filling up the petrol tank.
Funding: €304 million
Who: Co-founders, Aurélien de Meaux (CEO), Augustin Derville (CDO), Julien Belliato (COO)
Investors: PGGM (Dutch pension fund), Bpifrance, Eurazeo Infrastructure, Serena, Rive Private Investment, 574 Invest (investment branch of the national rail company, SNCF).
What's next: This staggering Series B round will go to consolidating Electra's position by deploying 2,200 stations across the 8 European countries in which they are present— representing 15k charging points — by 2030.
What: Scalinx, a manufacturer of signal conversion and processing chips for antennas.
Why: To enable analog-to-digital and digital-to-analog conversion of wide-band signals with low power consumption for wired and wireless communications, test and measurement equipment, and radars
Funding: €34 million
Who: Founder & CEO, Hussein Fakhoury
Investors: Thales, Go Capital, Bpifrance, WaterStart Capital, Normandie Participations, BNP Paribas Développement, Unexo
What's next: This new round of funding will enable the company to develop cutting-edge system-on-chip (SoC) solutions and expand its customer base.
What: Vulkam, a Deeptech company that develops amorphous metals (metallic glasses) known as "Vulkalloys®".
Why: To create unparalleled micro-mechanical parts, for use in industrial and medical equipment.
Funding: €34 million (of which €14 m equity)
Who: Founder & President, Sébastien Gravier
Investors: SEB industrial group & Bpifrance
What's Next: Vulkam will use the fresh funds to finance the 2025 operational launch of its first factory located in Isère and dedicated to the production of its new metals.
What: Enyo Pharma is a biotech specializing in producing trial medicines for rare kidney diseases.
Why: To enhance the quality of life and prevent end-stage renal failure and dialysis in patients with kidney diseases.
Funding: €27 million
Who: Co-founders Jacky Vonderscher , Laurène Meyniel-Schicklin, Dr Benoît de Chassey, Pr Patrice André, Dr Vincent Lotteau, Dr Jean-Jacques Garaud
Investors: OrbiMed, Morningside Ventures, AndEra Partners, Bpifrance InnoBio, & Bpifrance Large Ventures
What's Next: The raise will finance a new clinical study of their trial medicine, "Vonafexor", to be tested on Alport syndrome patients during the first half of this year and continue investments in the R&D of Vonafexor for use on other kidney diseases, such as autosomal dominant polycystic kidney disease (PKRAD).
What: Nabla, an AI assistant for doctors and healthcare professionals
Why: To allow healthcare professionals with their admin by generating written clinical notes and reports, across multiple medical sectors in seconds
Funding: €22 million
Who: Co-Founders Martin Raison, Delphine Groll, Alexandre Lebrun
Investors: Cathay Innovation, Zebox Ventures
What's next: The raise will enable Nabla to boost expansion across U.S. healthcare systems and continue transforming the way providers deliver care.
What: Hiboo, a construction tech SaaS platform.
Why: To help manufacturers optimize the use and energy efficiency of their site machinery/industrial equipment by making operations more efficient and environmentally responsible.
Funding: €9.3 million
Who: Co-Founders Clément Bénard & Marie de Raismes - Baron
Investors: Emerald Technology Ventures, Isai Build Venture, Future Industry Ventures, Ring Capital, Citizen Capital
What's next: The new funding will enable Hiboo to accelerate the development of new products, strengthen its teams, and fuel its international expansion, notably in Europe and the United States.
What: Womed, a biotech specializing in innovative and safe treatments.
Why: To free women from complex uterine pathologies such as infertility, uterine bleeding, and endometriosis.
Funding: €6 million
Who: Co-Founders, Gonzague Issenmann, Dr. Stéphanie Huberlant, Prof. Xavier Garric``
Investors: Irdi & Family-offices
What's next: Womed will use the funds to launch the commercialization of its intrauterine device against infertility.
